ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,783.00
-0.71%
S&P ASX All Technology
3,113.80
0.20%
Brent Oil
84.195
0.01%
US Dollar vs AUD
1.50177
-0.21%
Bitcoin
61,416.81
-0.64%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Gain Therapeutics Inc (GANX)

  7. Gain Therapeutics Inc (GANX) News

GANX

Gain Therapeutics (GANX)

Gain Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GANX
DateTimeSourceHeadlineSymbolCompany
25/06/202421:00GlobeNewswire Inc.Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:GANXGain Therapeutics Inc
17/06/202422:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
15/06/202406:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
14/06/202411:00GlobeNewswire Inc.Gain Therapeutics Announces Pricing of $11.0 Million Public OfferingNASDAQ:GANXGain Therapeutics Inc
14/06/202406:44GlobeNewswire Inc.Gain Therapeutics Announces Proposed Public OfferingNASDAQ:GANXGain Therapeutics Inc
14/06/202406:38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
30/05/202421:00GlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024NASDAQ:GANXGain Therapeutics Inc
15/05/202406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GANXGain Therapeutics Inc
15/05/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
14/05/202421:30GlobeNewswire Inc.Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
24/04/202423:25GlobeNewswire Inc.Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
08/04/202423:25GlobeNewswire Inc.Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerNASDAQ:GANXGain Therapeutics Inc
02/04/202400:25GlobeNewswire Inc.Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerNASDAQ:GANXGain Therapeutics Inc
26/03/202423:00GlobeNewswire Inc.Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
16/03/202405:30GlobeNewswire Inc.Gain Therapeutics to Present at Public Ventures Discovery DayNASDAQ:GANXGain Therapeutics Inc
06/03/202400:00GlobeNewswire Inc.Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
28/02/202406:00GlobeNewswire Inc.Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
22/02/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
15/02/202404:29GlobeNewswire Inc.Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightNASDAQ:GANXGain Therapeutics Inc
07/02/202401:56GlobeNewswire Inc.UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
07/02/202400:00GlobeNewswire Inc.Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
01/02/202409:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
01/02/202400:00GlobeNewswire Inc.Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateNASDAQ:GANXGain Therapeutics Inc
03/01/202408:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GANXGain Therapeutics Inc
03/01/202400:00GlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024NASDAQ:GANXGain Therapeutics Inc
02/01/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GANXGain Therapeutics Inc
20/12/202308:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:GANXGain Therapeutics Inc
02/12/202300:00GlobeNewswire Inc.Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis ModelNASDAQ:GANXGain Therapeutics Inc
30/11/202300:00GlobeNewswire Inc.Gain Therapeutics to Participate in AI Driven Drug Discovery SummitNASDAQ:GANXGain Therapeutics Inc
25/11/202305:01GlobeNewswire Inc.Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment OptionNASDAQ:GANXGain Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GANX

Your Recent History

LSE
SL31
Corp Andina 27
LSE
0AAC
Byggfakta Group Nordic H...
USOTC
GPDB
Green PolkaDot Box (CE)
NYSE
SCM
Stellus Capital Investment
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved